Core Viewpoint - Northeast Securities maintains an "overweight" rating for Yidu Technology (02158), highlighting significant improvements in market penetration in the medical intelligence sector and record-high gross margins for its self-developed i-series solutions during the fiscal year 2025 [1] Group 1: Market Penetration and Client Base - As of March 31, 2025, the company's big data platform serves 110 top hospitals in China and 44 regulatory agencies, covering over 4000 hospitals [1] - The Copilot product matrix completed deployments in over 30 tier-one hospitals within three months, creating a complete closed loop of "data governance - intelligent training - scenario implementation," significantly enhancing market penetration in medical intelligence [1] - The life sciences segment serves 132 clients, with a revenue retention rate of 87.51% among the top 20 clients, 16 of which are multinational pharmaceutical companies [1] Group 2: Financial Performance and Competitive Edge - The gross margin for the self-developed i-series solutions reached 33.5%, marking a historical high and underscoring the company's core competitiveness in the field of pharmaceutical research and development intelligence [1] - The company has been the main operating platform for "Shenzhen Huimin Insurance" for three consecutive years, with 6.09 million insured individuals in 2024; it has also operated "Beijing Huimin Insurance" for four years, accumulating over 15 million insured instances [1] - The platform has over 24 million active users, all of whom have completed at least one transaction, demonstrating strong user reach and market acceptance for health management services, laying a solid foundation for future commercialization [1]

Core Viewpoint - The medical device and consumables sectors, along with AI healthcare, are experiencing significant growth driven by favorable policies and market dynamics. Group 1: Medical Device and Consumables Sector - The Hong Kong medical ETF (159366) saw a rise of over 4.5% on July 30, with a trading volume nearing 600 million, benefiting from the active market for innovative drugs and devices [1] - The medical device ETF (159883) recorded a net inflow of 2.03 billion, ranking first among comparable funds, with a total of 7.14 billion in net inflows over nine consecutive days [1] - Policy expectations are positive, with high-value consumables expected to benefit from improved procurement policies, leading to a reduction in valuation pressure and a more stable long-term performance outlook for leading companies [1][3] Group 2: Policy Support and Market Dynamics - Continuous policy support for the medical consumables sector is shifting the focus from price wars to value wars, with the National Medical Insurance Bureau facilitating the pricing of innovative medical consumables [3] - The optimization of the 11th batch of national drug procurement rules aims to address the issue of price undercutting, allowing companies to maintain profit margins and focus on innovation [3][4] - The simplification of the approval process for innovative consumables is expected to accelerate their market entry, enhancing the support for clinically valuable new products [4] Group 3: AI Healthcare Sector - The AI healthcare sector is gaining momentum, with the 2025 World Artificial Intelligence Conference showcasing practical applications that address clinical challenges and promote scalable solutions [5] - The release of the "2025 Artificial Intelligence + Health Shanghai Practice" outlines a development path for AI healthcare, focusing on data flow issues and the integration of AI with biomedicine [5] - The Hong Kong medical ETF (159366) has become a key investment vehicle for AI healthcare, reflecting a 7.36% increase over the past week, driven by the sector's growth potential [6] Group 4: Investment Trends and Market Sentiment - The release of policy benefits has positioned medical consumables and AI healthcare as core investment areas, with significant capital inflow observed in these sectors [6] - The recovery of domestic medical equipment procurement is expected to boost upstream consumable demand, while AI healthcare companies in Hong Kong are attracting foreign investment due to their technological advantages [6][7] - The collaboration between the recovery of the CXO sector and AI healthcare is amplifying growth potential, as domestic CXO companies leverage cost advantages to secure more AI-driven drug development contracts [7]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 1.36% to 25,176.93 points, the Hang Seng Tech Index dropping by 2.72%, and the National Enterprises Index decreasing by 1.18% [2] - Technology stocks, particularly in the internet sector, saw significant losses, with JD.com, Alibaba, and Baidu each dropping over 2%, while Tencent fell more than 1% [2] - In contrast, AI healthcare concept stocks and medical equipment stocks surged, with Ping An Good Doctor rising over 11% and China Health Group increasing by 48% [2][4] AI Healthcare Sector - The AI healthcare and medical equipment sectors are experiencing rapid growth, driven by supportive government policies and increasing market demand [4] - The National Medical Products Administration announced measures to support the innovation of high-end medical devices, focusing on AI imaging diagnostics and surgical robots [4] - Beijing's "AI + Healthcare" action plan aims to establish an innovative ecosystem by 2027, promoting over 30 core technologies and innovative products [4] Oil and Gas Sector - Oil and gas equipment and services stocks performed well, with Shandong Graphite rising over 16% [4] - International oil prices rebounded, with Brent and WTI crude futures both increasing by over 3%, returning to around $70 per barrel [4] Automotive Sector - The automotive sector faced significant declines, with Li Auto dropping over 12% and other major players like BYD and Xpeng also experiencing losses [7] Semiconductor Sector - Semiconductor stocks weakened, with SMIC falling over 5% amid news that Nvidia placed a new order for 300,000 H20 chips with TSMC, impacting market sentiment negatively for local semiconductor suppliers [7][8]

Group 1 - The core viewpoint is that the pharmaceutical and biotechnology industry is expected to benefit from the recent outbreak of Chikungunya fever, with a gradual recovery in vaccine sector performance and potential valuation adjustments due to innovation attributes [1] - The pharmacy sector is exploring new business models in the context of medical insurance reforms, with non-pharmaceutical products emerging as a potential breakthrough direction [1] - The diagnostics sector is anticipated to improve due to the digestion of pandemic-related baselines and new demand arising from the current health landscape [1] Group 2 - The medium to long-term focus is on "innovation + AI healthcare + recovery," with innovative drugs and medical devices receiving clear support from the National Healthcare Security Administration, emphasizing differentiated innovation [1] - AI healthcare is gaining attention due to the World Artificial Intelligence Conference, with focus areas including diagnostic paradigms and drug development [1] - Recovery lines include a rebound in medical equipment procurement, as well as a restoration of demand in CXO and upstream life sciences [1] Group 3 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in new drug research, production, and sales from the Shanghai, Shenzhen, and Hong Kong markets to reflect the overall performance of innovative pharmaceutical companies [1] - Investors without stock accounts can consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiation Link C (014118) and Link A (014117) [1]

Core Viewpoint - The stock price of Sely Medical has declined significantly, reflecting challenges in its financial performance and market perception [1] Company Overview - Sely Medical operates in the pharmaceutical commercial sector, focusing on intensive in vitro diagnostics and medical consumables supply chain management [1] - The company is attempting to transition into the AI healthcare field, particularly in brain science and large model technologies [1] Financial Performance - As of July 29, 2025, Sely Medical's stock price is 31.62 yuan, down 1.53 yuan or 4.62% from the previous trading day [1] - The company reported a net profit loss forecast of 55 million to 66 million yuan for the first half of the year, indicating a year-on-year increase in loss magnitude [1] - The company has recovered 4.2 million yuan of overdue equity transfer payments but still faces 9.3 million yuan in outstanding payments [1] Market Activity - On July 29, the net outflow of main funds was 204.55 million yuan, accounting for 3.39% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds reached 42.78 million yuan [1] Credit Rating - Rating agencies have downgraded Sely Medical's credit rating to BB+ [1]

Core Viewpoint - After more than a month of overdue payments, Seli Medical has received part of the overdue equity transfer payment, but the company continues to face significant operational and financial pressures, leading to a drastic decline in revenue and net profit losses [1][4]. Group 1: Financial Performance - Seli Medical reported a projected net loss of between 55 million to 66 million yuan for the first half of the year, marking a year-on-year increase in losses of over 1053%, the worst mid-year performance since its listing [4]. - The company has experienced continuous net profit losses over the years, with cumulative losses reaching approximately 570 million yuan from 2021 to 2024 [4][5]. - The company's cash flow is under severe strain, with a cash balance of only 167 million yuan as of the end of March, while short-term borrowings reached 310 million yuan [3][7]. Group 2: Equity Transfer and Payments - Seli Medical has received a total of 17.5 million yuan in equity transfer payments, with an outstanding amount of 9.3 million yuan still owed by Rongda Zhiyuan No. 2 [1][2]. - The equity transfer involved the sale of a 51% stake in a subsidiary for 31 million yuan, with payments scheduled in five installments, of which the fourth installment was partially overdue [2]. Group 3: Business Strategy and Transformation - The company is attempting to pivot towards "AI medical" solutions to find new growth opportunities, despite the ongoing challenges in its core business [1][6]. - Seli Medical's main profit source, the IVD business, has seen significant revenue declines, while the SPD business, although growing, has insufficient margins to offset the losses from IVD [6]. - The company is exploring partnerships to develop digital systems for mental health treatment and aims to enter advanced fields like brain science and rare diseases [6][7]. Group 4: Market Reaction - Despite deteriorating fundamentals, Seli Medical's stock price has surged approximately 370% this year, driven by market enthusiasm for "AI+medical" and "innovative drugs" concepts [3][7].

Group 1 - The innovative drug ETF (560900) rose by 2.74% with a turnover of 30.12%, indicating active market trading [1] - The CSI Innovative Drug Industry Index (931152) increased by 2.82%, with notable gains in constituent stocks such as Tigermed (300347) up 10.32%, Jiuzhou Pharmaceutical (603456) up 10.01%, and WuXi AppTec (603259) up 6.30% [1] - The innovative drug ETF reached a new high of 1.019 yuan during the morning session, marking the highest price since the beginning of the year, with a half-day trading volume of 18.8945 million yuan, also a record since its listing [1] Group 2 - Huazhang Securities noted that high-value medical consumables have been under pressure from centralized procurement, but the market is now refocusing on low-priced medical devices and IVD sectors, with specific interest in artificial crystals, endoscopic consumables, orthopedics, and neurosurgery [2] - The innovative drug sector continues to gain traction, becoming one of the main market directions, with long-term investment value in innovative drugs, innovative devices, and AI healthcare [2] - The CSI Innovative Drug Industry Index is designed to reflect the overall performance of listed companies involved in innovative drug research and development, selecting no more than 50 representative companies [2]

Investment Rating - The industry investment rating is "Overweight" [2] Core Viewpoints - The pharmaceutical sector is experiencing a divergence among its sub-industries, entering a phase of logical exploration [5] - The pharmaceutical index has outperformed the CSI 300 index, with a 1.9% increase this week, ranking 19th in terms of performance [17][19] - The highest valuation sub-industry is vaccines, with a PE (TTM) of 62X, while the lowest performing sub-industry is chemical preparations, which decreased by 2.02% [22] Summary by Sections Market Review - The pharmaceutical index rose by 1.9%, outperforming the CSI 300 index by 0.21 percentage points and the Shanghai Composite Index by 0.23 percentage points [17] - As of July 25, the PE (TTM) for the pharmaceutical industry is 28X, which is below the historical average of 33X [19] - Among 13 sub-industries, 11 saw increases, with medical research outsourcing leading at an 8.29% rise [22] Stock Performance - In the A-share market, 72.36% of the 474 pharmaceutical stocks increased in value this week [24] - The top ten performing stocks include Haitai Biological (+46.93%) and Zhendong Pharmaceutical (+42.89%) [25] - In the Hong Kong market, 66.67% of 114 stocks rose, with the top performer being MicroPort Medical (+28.86%) [31] Weekly Insights - The divergence in sub-industries is attributed to the focus on innovation and potential high-value products, with medical devices gaining market attention [5] - The National Healthcare Security Administration's guidance against price-only bidding has renewed interest in the medical device and IVD sectors [5] - The report maintains a bullish outlook on the pharmaceutical sector, emphasizing innovation in hard technology, including innovative drugs and devices [37] Investment Strategy - The investment strategy is divided into two main areas: innovative drug sector and other sectors [38] - Key recommendations include Zai Lab, BGI Genomics, and Junshi Biosciences, with a focus on oncology and innovative drug development [38] - Other sectors of interest include medical hard technology, medical consumption, and companies with significant overseas business [39][41]

Market Overview - On July 28, 2025, A-shares saw collective gains across the three major indices, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.44%, and the ChiNext Index by 0.96%. The total trading volume in the Shanghai and Shenzhen markets exceeded 1.7 trillion yuan [1]. Innovation Drug Sector - Innovation drug-related ETFs led the market with significant gains, including the Innovation Drug ETF Hong Kong-Shenzhen (159622) rising by 4.10%, and the Hong Kong Innovation Drug 50 ETF (513780) increasing by 4.04% [1]. - A notable announcement from Heng Rui Medicine involved a potential license-out collaboration with GlaxoSmithKline (GSK) worth up to $12.5 billion, covering a clinical-stage respiratory innovation drug and up to 11 non-clinical candidates. This news led to a surge in Heng Rui's stock, reaching a four-year high in A-shares and over 16% increase in H-shares [2]. ETF Performance - The top-performing ETFs included several innovation drug-related funds, with multiple ETFs achieving gains above 3.70% [1]. - Conversely, the energy sector faced declines, with the top ETF, the Sci-Tech Comprehensive Aluminum ETF (589300), dropping by 14.01% [3]. Trading Activity - The trading volume for the Short-term Bond ETF (211360) was the highest at 33.9 billion yuan, followed by the Silver Hua Daily ETF (511880) at 21.0 billion yuan [4]. - The turnover rate for the Benchmark National Bond ETF (511100) was the highest at 552.67%, indicating strong trading activity in this segment [5][6].

Company Overview - 德适生物科技股份有限公司 (德适生物) has submitted an IPO application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] - Established in 2016 and headquartered in Hangzhou, Zhejiang, the company focuses on AI-driven medical imaging solutions, particularly its core product, iMedImage™ [1][2] - The company has completed multiple rounds of financing, achieving a post-investment valuation of 2.56 billion yuan after the latest round in June 2025 [1] Product and Technology - 德适生物's core product, iMedImage™, is a leading medical imaging base model that supports 19 imaging modalities and covers over 90% of clinical scenarios [4][11] - The company has developed a complete automated chromosome analysis pipeline, including AI AutoVision® and MetaSight® systems, which have received regulatory approvals [4][5] - The AI AutoVision® is expected to be the world's first AI-driven chromosome karyotype analysis system upon approval from the National Medical Products Administration [4] Market Position and Financial Performance - 德适生物 has established a distribution network of over 75 distributors, covering more than 400 healthcare centers across 31 provinces in China [6] - The company reported revenues of 52.84 million yuan and 70.35 million yuan for 2023 and 2024, respectively, with a year-on-year growth of 33.1% [5] - In 2024, the company achieved a gross profit margin of 65.5%, positioning it among the top in the medical device industry [5] Industry Context - The medical imaging AI industry faces challenges such as low standardization of multimodal data and a shortage of skilled professionals, creating a demand for efficient AI tools [2] - The chromosome karyotype analysis market is highly concentrated, with international giants holding 95% of the market share; 德适生物 has captured 30.6% of the market following the launch of its innovative products [10][7] - The reproductive health medical device market in China is projected to grow significantly, with an expected market size of 71 billion yuan by 2024 and over 173 billion yuan by 2035 [7][10]